Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy

We report on the clinical history of a 49-year-old female with metastatic pancreatic cancer. She was initially treated with standard chemotherapy as per current guidelines. She was found to have both a BRAF and P53 mutation, and received dabrafenib and trametinib with deep responses, both radiograph...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasankan, Shenthol, Rebuck, Lorraine, Darrah, Gloria, Harari Turquie, Moises, Rabinowitz, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670384/
https://www.ncbi.nlm.nih.gov/pubmed/33250737
http://dx.doi.org/10.1159/000510096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670384/
https://www.ncbi.nlm.nih.gov/pubmed/33250737
http://dx.doi.org/10.1159/000510096

Ejemplares similares